Medical treatment of advanced renal cell carcinoma: Present options and future directions

Cancer Treatment Reviews

Volumn 22, Issue 2, 1996, Pages 85-104

  Canobbio, Luciano ^a   Miglietta, Loredana ^a   Boccardo, Francesco ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANDROGEN; ANTIESTROGEN; ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; ELLIPTINIUM; ETOPOSIDE; FLOXURIDINE; GAMMA INTERFERON; GEMCITABINE; GESTAGEN; INTERFERON; INTERLEUKIN 2; LOMUSTINE; LONIDAMINE; MEDROXYPROGESTERONE ACETATE; MITOMYCIN C; NAFOXIDINE; NAVELBINE; TAMOXIFEN; TENIPOSIDE; TESTOSTERONE PROPIONATE; TUMOR NECROSIS FACTOR; VINBLASTINE; VINCRISTINE; VINDESINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; DRUG EFFICACY; HORMONAL THERAPY; HUMAN; KIDNEY CARCINOMA; KILLER CELL; METASTASIS; PATIENT SELECTION; PROGNOSIS; REVIEW;

EID: 0030036462     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(96)90029-8     Document Type: Review

References (123)

1. Kirkman, H. (1959) Estrogen induced tumors of the kidney in the Syrian hamster. NCI Monogr. 1: 1-59.
2. Bloom, H. J. G., Baker, W. K., Dukes, C. E. & Mitchel, B. C. V. (1963) Hormone-dependent tumours of the kidney II. Effect of the endocrine ablation procedures on the transplanted oestrogen-induced renal tumours in the Syrian hamsters. Br. J. Cancer 17: 646-656.
3. Matsuda, M., Nakaro, E. & Osofune, M. (1976) A clinical study on real carcinoma. Jap. J. Urol. 67: 635-646.
4. Bloom, H. J. G. (1973) Hormone-induced and spontaneous regression of metastatic renal cancer. Cancer 32: 1066-1071.
5. Concolino, G., Marocchi, A., Conti, C., Tengalia, R., Di Silverio, F. & Bracci, U. (1978) Human renal cell carcinoma as a hormone-dependent tumor. Cancer Res. 38: 4340-4344.
6. Chen, L, Weiss, F. R. & Chaichik, S. (1980) Steroid receptors in human renal cell carcinoma. Int. J. Med. Sci. 16: 756-761.
7. Pearson, J., Friedman, M. A. & Hoffman, P. G. Jr. (1981) Hormone receptors in renal cell carcinoma. Their utility as predictors of response to endocrine therapy. Cancer Chemother. Pharmacol. 6: 151-154.
8. Pizzocaro, G., Piva, L., Di Fronzo, G., Ronchi, E. & Miodini, P. and the Lombardi Group (1983) Hormone treatment and sex steroid receptors in metastatic renal cell carcinoma: report of a multicentric prospective study. Tumori 69: 215-220.
9. Bloom, H. J. G. (1971) Medroxyprogesterone in the treatment of metastatic renal cancer. Br. J. Cancer 25: 250-256.
10. Harris, D. T. (1983) Hormonal therapy and chemotherapy of renal-cell carcinoma. Semin. Oncol. 10: 422-430.
11. Boccardo, F. (1991) Therapeutic challenges in the medical management of renal cancer. Forum: Trends Exp. Clin. Med. 2: 143-156.
12. Hrushesky, W. J. & Murphy, G. P. (1977) Current status of the therapy of advanced renal carcinoma. J. Surg. Oncol. 9: 277-285.
13. Kuebler, J. P., Hogan, T. R, Trump, D. L. & Bryan, G. T. (1984) Phase II study of continuous 5-day vinblastine infusion in renal adenocarcinoma. Cancer Treat. Rep. 69: 925-926.
14. Tannock, I. F. & Evans, W. K. (1985) Failure of 5-day vinblastine infusion in the treatment of patients with renal cell carcinoma. Cancer Treat. Rep. 69: 226-228.
15. Crivellari, D., Tumolo, S., Frustaci, S. et al. (1987) Phase II study of five-day continuous infusion of Vinblastine in patients with metastatic renal-cell carcinoma. Am. J. Clin. Oncol. 10: 231-233.
16. Fosså, S.D., Denis, L., Van Oosterom, A.T., De Pauw, M. & Stoter, G. (1983) Vindesine in advanced renal cancer. A study of the EORTC Genito-urinary Tract Cancer Cooperative Group, Eur. J. Cancer 19: 473-475.
17. Canobbio, L, Boccardo, F., Guarneri, D. et al. (1991) Phase II study of Navelbine in advanced renal cell carcinoma. Eur. J. Cancer 27: 804-805.
18. Hire, E. A. & Samson, M. K. (1979) Use of VM-26 as a single agent in the treatment of renal carcinoma. Cancer Clin. Trials 2: 293-295.
19. Hahn, R. G., Bauer, M., Wolter, J., Creech, R., Bennett, J. M. & Wampler, G. L. (1979) Phase II study of single-agent therapy with megestrol acetate, VP-16-213, cyclophosphamide and dianhydrogalactitol in advanced renal cell cancer. Cancer Treat. Rep. 63: 513-515.
20. Moore, G. E., Brass, D. J., Ansman, R. et al. (1968) Effects of chlorambucil (NSC-3088) in 374 patients with advanced cancer. Cancer Chemother. Rep. 52: 641-653.
21. Mittelmann, A., Albert, D. J. & Murphy, G. P. (1973) Lomustine treatment of metastatic renal cell carcinoma. J.A.M.A. 225: 32-35.
22. Boccardo, F., Canobbio, L., Calabria, C., Guarneri, D. & Santi, L. (1991) Chemotherapy of renal cancer. In: Giuliani, L., Boccardo, F., Santi, L. & Pescatore, D., eds, New Trends in Diagnosis and Treatment of Renal Cancer. Roma: Acta Medica Edizioni, pp. 243-252.
23. Caillé, P., Mondesir, J. M., Droz, J. P. et al. (1985) Phase II trial of Elliptinium in advanced renal cell carcinoma. Cancer Treat. Rep. 69: 901-902.
24. Weinermann, B. H., Eisenhauer, E. A. & Besner, J. G. (1986) Phase II study of lonidamine in patients with metastatic renal cell carcinoma. A National Cancer Institute of Canada Clinical Trials Group study. Cancer Treat. Rep. 70: 751-754.
25. Yagoda, A., Abi-Rached, B. & Petrylak, D. (1995) Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin. Oncol. 22: 42-60.
26. Oudard, S., Bouleuc, C., Lotz, J. P. et al. (1994) Phase I-II study combining high-dose tamoxifene (HD-TMX) as a modulator of multidrug resistance (MDR) with vinblastine (VBL) and α2b interferon (IFN) in metastatic kidney carcinoma (MKC). Proc. Am. Soc. Clin. Oncol. 13: 756, p. 243.
27. Fojo, A. T, Shen, D. W., Mickley, L. A., Pastan, I. & Gottesman, M. (1987) Intrinsic drug resistance in kidney cancers is associated with expression of a human multidrug resistance gene. J. Clin. Oncol. 5: 1922-1928.
28. Mickisch, G. H., Roehrich, K., Koessig, J., Forster, S., Tschada, R. K. & Alken, P.M. (1990) Mechanism and modulation of multidrug resistance in primary human renal cell carcinoma. J. Urol. 144: 755-759.
29. Hrushesky, W. J., von Roemeling, R., Lanning, R. M. & Rabatin, J. T. (1990) Circadian-shaped infusions of floxuridine for progressive metastatic renal cell carcinomas. J. Clin. Oncol. 8: 1504-1513.
30. Miglietta, L., Canobbio, L., Cannata, D. et al. (1994) Low activity of circadian continuous fluorodeoxyuridine (FUDR) chemotherapy in poor prognosis metastatic renal cancer. Oncol. Rep. 1: 121-123.
31. Wilkinson, M., Stagg, R., Grobman, B., Carroll, P. & Venook, A. (1990) A phase II study of constant rate FUDR infusion in patients with metastatic renal cell cancer. Proc. Am. Soc. Clin. Oncol. 9A: 538.
32. Damascelli, B., Marchiano, A., Spreafico, C. et al. (1990) Circadian continuous chemotherapy of renal cell carcinomas with an implantable, programmable infusion pump. Cancer 66: 237-241.
33. Bjarnason, G. A., Hrushesky, W. J. M., Diasio, R. et at. (1994) Flat versus circadian modified 14 day infusion of FUDR for advanced renal cell cancer (RCC): a phase-III study. Proc. Am. Soc. Clin. Oncol. 13: 718, p. 233.
34. Canobbio, L, Miglietta, L & Boccardo, F. (1995) FUDR da solo o in combinazione con i BRM nel carcinoma renale avanzato. Forum: Trends Exp. Clin. Med. 5.1 (Suppl. 2): 33-37.
35. Horoszewicz, J. S. & Murphy, G. P. (1989) An assessment of the current use of human interferons in therapy of urological cancers. J. Urol. 142: 1173-1181.
36. Cantell, K., Hervonen, S. & Mogensen, K. E. (1975) Human leukocyte interferon production, purification, and animal experimental results. In Vitro (Rockville) 25-38.
37. Muss, H. B. (1991) Renal cell carcinoma. In: De Vita, V.T., Hellmann, S. & Rosenberg, S.A., eds, Biologic Therapy of Cancer. Philadelphia: J. B. Lippincott Company, pp. 298-311.
38. Porzsolt, F., Messerer, D., Hautmann, R. et al. (1988) Treatment of advanced renal cell cancer with recombinant interferon alpha as a single agent and in combination with medroxyprogesterone acetate. A randomized multicenter trial. J. Cancer Res. Clin. Oncol. 114: 95-100.
39. Rinehart, J., Malspeis, L., Young, D. & Neidhart, J. (1986) Phase I/II trial of human recombinant beta-interferon serine in patients with renal cell carcinoma. Cancer Res. 46: 5364-5367.
40. Garnick, M. B., Reich, S.D., Maxwell, B., Coval-Goldsmith, S., Richie, J. P. & Rudnick, S.A. (1988). Phase I/II study of recombinant interferon gamma in advanced renal cell carcinoma. J. Urol. 139: 251-255.
41. Rinehart, J. J., Malspeis, L, Young, D. & Neidhart, J. A. (1986) Phase I/II trial of human recombinant interferon gamma in renal cell carcinoma. J. Biol. Response Mod. 5: 300-308.
42. Quesada, J. R., Kurzrock, R., Sherwin, S. A. & Gutterman, J. U. (1987) Phase II studies of recombinant human interferon gamma in metastatic renal cell carcinoma. J. Biol. Response Mod. 6: 20-27.
43. Muss, H. B., Costanzi, J., Leavitt, R. et al. (1987) Recombinant alpha interferon in renal cell carcinoma: a randomized trial of two routes of administration. J. Clin. Oncol. 5: 286-291.
44. Kish, J., Ensley, J., Al-Sarraf, M., Ratanatharathorn, V, Karane, C. & Galicky, P. (1986) Activity of serine substituted recombinant DNA β interferon (IFN-β) in patients with metastatic and recurrent renal cell cancer. Proc. Amer. Ass. Cancer Res. 2: 184.
45. Fosså, S. D. (1989) Current treatment approaches to renal cell carcinoma. In: Kaye, S. B., ed., Progress in the Treatment of Renal Cell Carcinomas, Eversley Way, Surrey, U.K.: Medical Action Communications Ltd., pp. 12-21.
46. Holdener, E. E. (1989) The efficacy and safety of human recombinant interferon alpha-2a in metastatic renal cell carcinoma. In: Kaye, S. B., ed., Progress in the Treatment of Renal Cell Carcinoma, Eversley Way, Surrey, U.K.: Medical Action Communications Ltd., pp. 56-62.
47. Umeda, T. & Niijima, N. (2986) Phase II study of alpha interferon on renal cell carcinoma: summary of three collaborative trials. Cancer 58: 1231-1235.
48. Fosså, S. D., Kramar, A. & Droz, J.-P. (1994) Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-α. Eur. J. Cancer 30A: 1310-1314.
49. Quesada, J. R., Swanson, D. A. & Gutterman, J. U. (1985) Phase II study of interferon alpha in metastatic renal-cell carcinoma: a progress report. J. Clin. Oncol. 3: 1086-1092.
50. Kirkwood, J. M., Harris, J. E., Vera, R. et al. (1985) A randomized study of low and high doses of leuckocyte α-interferon in metastatic renal cell carcinoma: The American Cancer Society collaborative trial. Cancer Res. 45: 863-871.
51. Buzaid, A. C., Robertone, A., Kisala, C. & Salmon, S. E. (1987) Phase II study of interferon alfa-2α, recombinant (Roferon-A) in metastatic renal cell carcinoma. J. Clin. Oncol. 5: 1083-1089.
52. Quesada, J. R., Rios, A., Swanson, D., Trown, P. & Gutterman, J. U. (1985) Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma. J. Clin. Oncol. 3: 1522-1528.
53. Figlin, R. A., deKernion, J. B., Mukamel, E., Palleroni, A. V., Itri, L.M. & Sarna, G. P. (1988) Recombinant interferon alfa-2a in metastatic renal cell carcinoma: assessment of antitumor activity and anti-interferon antibody formation. J. Clin. Oncol. 6: 1604-1610.
54. Spiegel, R. J., Spicehandler, J. R., Jacobs, S. L. & Oden, E. M. (1986) Low incidence of serum neutralizing factors in patients receiving recombinant alfa-2b interferon (Intron A). Am. J. Med. 80: 223-228.
55. Itri, L. M., Campion, M., Dennin, R. A., et al. (1987) Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon alpha-2a by intramuscular injection. Cancer 59: 668-674.
56. Falcone, A., Cianci, C., Ricci, S. et al. (1993) Alfa 2B interferon plus floxuridine in metastatic renal cell carcinoma. Cancer 72: 564-568.
57. Trump, D. L., Elson, P. J., Borden, E. C. et al. (1987) High-dose lymphoblastoid interferon in advanced renal cell carcinoma: an Eastern Cooperative Oncology Group study. Cancer Treat. Rep. 71: 165-169.
58. Elson, P. J., Witte, R. S. & Trump, D. L (1988) Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res. 48: 7310-7313.
59. Wadler, S. & Schwartz, E. L. (1990) Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res. 50: 3473-3486.
60. Fosså, S. D., De Garis, S. T., Heier, M. S., Flokkamann, A. & Lien, H. H. (1986) Recombinant interferon α-2a with or without Vinblastine in metastatic renal cell carcinoma. Cancer. 57: 1700-1704.
61. Fosså, S. D., Raabe, N. & Moe, B. (1989) Recombinant interferon alpha with or without Vinblastine in metastatic renal carcinoma. Results of a randomized phase II study. Br. J. Urol. 64: 468-471.
62. Neidhart, J. A., Anderson, S. A., Harris, J. E. et al. (1991) Vinblastine fails to improve response of renal cancer to interferon alpha-n1: high response rate in patients with pulmonary metastases. J. Clin. Oncol. 9: 832-840.
63. Creagan, E. T., Kovach, J. S., Long, H. S. & Richardson, R. L. (1986) Phase I study of recombinant leukocyte A human interferon combined with BCNU in selected patients with advanced cancer. J. Clin. Oncol. 4: 408-413.
64. Muss, H. B., Welander, C., Caponera, M. et al. (1985) Interferon and doxorubicin in renal cell carcinoma. Cancer Treat. Rep. 69: 721-722.
65. Wadler, S., Einzif, A. I., Dutcher, J. P., Ciobanu, N., Landau, L. & Wiernik, P. H. (1988) Phase Il trial of recombinant alpha-2b-interferon and low-dose cyclophosphamide in advanced melanoma and renal cell carcinoma. Am. J. Clin. Oncol. 11: 55-59.
66. Czarniecki, C. W. (1984) Synergistic antiviral and antiproliferative activities of E. Coli derived human alpha, beta and gamma interferons. J. Urol 49: 490-96.
67. Quesada, J. R., Evans, L., Saks, S. R. & Gutterman, J. U. (1988) Recombinant interferon alpha and gamma in combination as treatment for metastatic renal cell carcinoma. J. Biol. Response Mod. 7: 234-239.
68. de Mulder, P. H. M., Debruyne, F. M., Geboers, A. D., Strijk, S. & Damsma, O. (1988) Recombinant alpha- and gamma-interferon in the treatment of advanced renal cell carcinoma. J. Urol. 139: 294A.
69. de Mulder, P. H. M., Debruyne, F. M. J., Franssen, M. P. H. & Rikken, G. (1991) Interferons and tumor necrosis factor in renal cell carcinoma. In: Giuliani, F., Boccardo, F., Santi, L. & Pescatore, D., eds, New Trends in Diagnosis and Treatment of Renal Cancer. Roma: Acta Medica Edizioni, pp. 333-338.
70. Foon, K., Doroshow, J., Bonnem, F. et al. (1988) A prospective randomized trial of alpha-2b interferon/gamma-interferon or the combination in advanced metastatic renal cell carcinoma. J. Biol. Response Med. 7: 540-545.
71. Figlin, R. A., De Kernion, J., Sarna, G., Moldawer, N. & Saks, S. (1988) Phase II study of recombinant tumor necrosis factor in patients with metastatic renal carcinoma and malignant melanoma. Proc. Am. Soc. Clin. Oncol. 7: A652.
72. Creagan, E. T., Buckner, J. C., Hahn, R. G., Richardson, R. R., Schaid, D. J. & Kovach, J. S. (1988) An evaluation of recombinant leukocyte A interferon with aspirin in patients with metastatic renal cell cancer. Cancer 61: 1787-1791.
73. Fosså, S. D. (1987) Improved subjective tolerability of interferon by combination with prednisolone. Eur. J. Cancer Clin. Oncol. 23: 875-876.
74. Rosenberg, S. A., Lotze, M. T. & Muul, L. M. (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med. 313: 1485-1492.
75. Rosenberg, S. A., Lotze, M. T., Muul, L. M. et al. (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N. Engl. J. Med. 316: 889-897.
76. Rosenberg, S. A., Lotze, M. T., Yang, J. C. et al. (1989) Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann. Surg. 210: 474-484.
77. Negrier, S., Philip, T., Stoter, G. et al. (1989) Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study. Eur. J. Cancer Clin. Oncol. 25 (Suppl.3): 21-28.
78. Bajorin, D. F., Sell, K. W, Richards, J. M. et al. (1990) A randomized trial of interleukin-2 plus lymphokine-activated killer cells versus interleukin-2 alone in renal cell carcinoma. Proc. Am. Assoc. Cancer Res. 31: A1106.
79. Linehan, W. M., Shiley, W. U. & Parkinson, D. R. (1993) Cancer of the kidney and ureter. In: De Vita, V. T., Hellman, S. & Rosenberg, S. A., eds, Cancer: Principles and Practice of Oncology. Fourth Edition. Philadelphia: J. B. Lippincot Co., pp. 1023-1051.
80. Margolin, K. A., Raynor, A. A., Hawkins, M. J. et al. (1989) lnterleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J. Clin. Oncol. 7: 486-498.
81. West, W. H., Tauer, K. W., Yannelli, J. R. et al. (1987) Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N. Engl. J. Med. 316: 898-905.
82. Palmer, P. A., Atzopodien, J., Philip, T. et al. (1993) A comparison of 2 modes of administration of recombinant interleukin-2: continuous intravenous infusion alone versus subcutaneous administration plus Interferon alpha in patients with advanced renal cell carcinoma. Cancer Biotherapy 8: 123-136.
83. Rosenberg, S. A., Lotze, M. T., Yang, J. C. et al. (1993) Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J. Natl. Cancer Inst 85: 622-632.
84. Yang, J. C., Topalian, S. L., Parkinson, D. et al. (1994) Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report. J. Clin. Oncol. 12: 1572-1576.
85. Rosenberg, S. A., Spiess, P. & Lafreniere, R. (1986) A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233: 1318-1321.
86. Rosenberg, S. A., Parckard, B. S., Aebersold, P. M. et al. (1988) Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N. Engl. J. Med. 319: 1676-1680.
87. Griffith, K. D., Read, E. J., Carrasquillo, J. A. et al. (1989) In vivo distribution of adoptive, transferred indium-111-labeled tumor infiltrating lymphocytes and peripheral blood lymphocytes in patients with metastatic melanoma. J. Natl. Cancer Inst. 81: 1709-1717.
88. Rosenberg, S. A., Lotze, M. T., Yang, J. C. et al. (1989) Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J. Clin. Oncol. 7: 1863-1874.
89. Atkins, M. B., Sparano, J., Fisher, R. I. et al. (1991) Randomized phase II trial of high-dose IL-2 either alone or in combination with Interferon alpha 2B in advanced renal cell carcinoma. Proc. Am. Soc. Clin. Oncol. 10: A526.
90. Atzpodien, J., Korfer, A., Franks, C. R., Poliwoda, H. & Kirchner, H. (1990) Home therapy with recombinant interleukin-2 and Interferon alpha-2b in advanced human malignancies. Lancet 335: 1509-1513.
91. Atzpodien, J., Lopez Hänninen, E., Kirchner, H. et al. (1995) Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma. J. Clin. Oncol. 13: 497-501.
92. Sznol, M., Thurn, A. & Parkinson, D. R. (1989) Overview of interleukin-2 trials in patients with renal cell carcinoma. A report of a European multicentre study. Eur. J. Cancer Clin. Oncol. 25: S21.
93. Atzpodien, J., Kirchner, H., Lopez Hänninen, E., Deckert, M., Franzke, A. & Poliwoda, H. (1994) European studies of interleukin-2 in metastatic renal cell cancer. Proc. Am. Soc. Clin. Oncol. 13: 773, p. 247.
94. Lissoni, P., Barni, S., Tancini, G. et al. (1994) A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma. Br. J. Cancer 69: 196-199.
95. Lissoni, P., Barni, S., Tancini, G. et al. (1993) Immunoendocrine therapy with interleukin-2 (IL-2) and medroxyprogesterone acetate (MPA): a randomized study with or without MPA in metastatic renal cancer patients during IL-2 maintenance treatment after response or stable disease to IL-2 subcutaneous therapy. Tumori 79: 246-249.
96. Droller, M. J. (1987) Immunotherapy of metastatic renal cell carcinoma with polyinosinic polycytidylic acid. J. Urol. 1: 137-202.
97. De Kernion, J. B. & Ramming, J. B. (1980) The therapy of renal adenocarcinoma with immune RNA. Invest. Urol. 17: 378-383.
98. Richie, J. P., Wand, B. S. & Steele, G. D. (1984) Current treatment of metastatic renal cell carcinoma with xenogeneic immune ribonucliec acid. J. Urol. 131: 236-239.
99. Marshall, M. E., Mendelsohn, L., Butler, K., et al. (1987) Treatment of metastatic renal cell carcinoma with coumarin (1,2-benzopyrone) and cimetidine: a pilot study. J. Clin. Oncol. 5: 862-666.
100. Marshall, M. E., Butler, K., Fried, A., Way, S. & Kostenbauder, H. J. (1991) Treatment of metastatic renal carcinoma with coumarin (1,2-benzopyrone) and cimetidine: a critical review. In: Giuliani, L., Boccardo, F., Santi, L. & Pescatore, D., eds, New Trends in Diagnosis and Treatment of Renal Cancer. Roma: Acta Medica Edizioni e Congressi, pp. 269-282.
101. Dexeus, F. H., Logothetis, C. J., Sella, A. et al. (1990) Phase II study of coumarin and cimetidine in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 8: 325-330.
102. Morales, A. & Edinger, D. (1982) Cytoreductive surgery and systemic bacillus Calmette-Guerin therapy in metastatic renal cancer. A phase II trial. J. Urol. 127: 230-232.
103. Dimitrov, N. V., Arnold, D., Munson, J., Singh, T., Borst, J. & Stott, P. (1985) A phase II study of thymosin fraction 5 in the treatment of metastatic renal cell carcinoma. Cancer Treat Rep. 69: 137-138.
104. McCune, C., O'Donnel, R., Marquis, D. & Sahasrabudhe, D. (1991) Specific immunotherapy of renal carcinoma by autologous tumor cells vaccines. In: Giuliani, L., Boccardo, F., Santi, L. & Pescatore, D., eds, New Trends in Diagnosis and Treatment of Renal Cancer. Roma: Acta Medica Edizioni e Congressi, pp. 349-353.
105. Yoshida, S. O. (1986) Proximal renal tubule surface membrane antigens identified in primary and metastatic renal cell carcinoma. Arch. Patol. Lab. Med. 110: 825-832.
106. Osband, M. E., Lavin, P. T., Babayan, R. J. et al. (1990) Effect of autolymphocyte therapy on survival and quality of life in patients with metastatic renal-cell carcinoma. Lancet 335: 994-998.
107. McCabe, M. S., Stablein, D. & Hawkins, M. J. (1991) The modified GROUP C experience: phase III randomized trials of IL-2 vs IL-2/LAK in advanced renal cell carcinoma and advanced melanoma. Proc. Am. Soc. Clin. Oncol. 10: 714.
108. Philip, T. (1989) Recombinant human interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: the European experience. Proc. Am. Soc. Clin. Oncol. 8: A507.
109. Fisher, R. I., Coltman, C. A., Doroshow, J. H. et al. (1988) Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. Ann. Intern. Med. 108: 518-523.
110. Weiss, G. R., Margolin, K. A., Aronson, F. R. et al. (1992) A randomized phase II trial of continuous infusion interleukin-2 or bolus injection IL-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma. J. Clin. Oncol. 10: 275-281.
111. Gaynor, E. R., Weiss, G. R., Margolin, K. A. et al. (1990) Phase I study of high-dose continuous infusion recombinant interleukin-2 and autologous lymphokine-activated killer cells in patients with metastatic or unresectable malignant melanoma and renal cell carcinoma. J. Natl. Cancer Inst. 82: 1397-1402.
112. Sella, A., Zukiwski, A., Robinson, E. et al. (1994) Interleukin-2 (IL-2) with interferon-a (IFN-α) and 5-fluorouracil (5-FU) in patients (PTS) with metastatic renal cell cancer (RCC). Proc. Am. Soc. Clin. Oncol. 13: 733
113. Mittelman, A., Huberman, M., Puccio, C. et al. (1990) A phase I study of recombinant human interleukin-2 and alpha-interferon-2 a in patients with renal cell cancer, colorectal cancer, and malignant malanoma. Cancer 66: 664-669.
114. Bartsch, H. H., Alder, M., Ringert, R. H. et al. (1990) Sequential therapy of recombinant interferon-alpha (IFN-A) and recombinant interleukin-2 (IL-2) in patients with advanced renal cell cancer (RCC). Proc. Am. Soc. Clin. Oncol. 9: 556.
115. Negrier, S., Mercatello, A., Tognet, E. et al. (1990) Interleukin-2 (IL-2) therapy in 64 patients with metastatic renal cell carcinoma. Proc. Am. Soc. Clin. Oncol. 9: 760.
116. Figlin, R. A., Belldegrun, A., Moldawer, N. et al. (1992) Concomitant administration of recombinant human interleukin-2 and recombinant Interferon alfa-2a: an active outpatient regimen in metastatic renal cell carcinoma. J. Clin. Oncol. 10: 414-421.
117. Besana, C., Borri, A., Bucci. E. et al. (1994) Treatment of advanced renal cell cancer with sequential intravenous recombinant interleukin-2 and subcutaneous α-interferon. Eur. J. Cancer 3: 1292-1298.
118. Facendola, G., Locatelli, M. C., Pizzocaro, G. et al. (1995) Subcutaneous administration of interleukin-2 and interferon-alpha-2b in advanced renal cell carcinoma: a confirmatory study. Br. J. Cancer 72: 1531-1535.
119. Vuoristo, M., Jantunen, I., Pyrhonem, S. et al. (1994) A combination of subcutaneous recombinant interleukin-2 and recombinant interferon-of in the treatment of advanced renal cell carcinoma or melanoma. Eur. J. Cancer 30A: 530-532.
120. Canobbio, L., Curotto, A., Cannata, D., et al. (1995) Combination therapy with subcutaneous interleukin-2 and interferon-a in advanced renal cancer patients with poor prognostic factors. Anticancer Res. 15: 1-4.
121. Lissoni, P., Barni, S., Ardizzoia, A. et al. (1994) Prognostic factors of the clinical response to subcutaneous immunotherapy with interleukin-2 alone in patients with metastatic renal cell carcinoma. Oncol. 51: 59-62.
122. Canobbio, L., Rubagotti, A., Miglietta, L. et al. (1995) Prognostic factors for survival in patients with advanced renal cell carcinoma treated with interleukin-2 and interferon-α. J. Cancer Res. Clin. Oncol. 121: 753-756.
123. Palmer, P. A., Vinke, J., Philip, T. et al. (1992) Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann. Oncol. 3: 475-480.